Status:
COMPLETED
Addressing Involuntary Movements in Tardive Dyskinesia
Lead Sponsor:
Auspex Pharmaceuticals, Inc.
Conditions:
Tardive Dyskinesia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Eligibility Criteria
Inclusion
- History of using a dopamine receptor antagonist for at least 3 months
- Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening
- Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications
- Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months
- History of being compliant with prescribed medications
- Able to swallow study drug whole
- Be in good general health and is expected to attend all study visits and complete study assessments
- Female subjects must not be pregnant and must agree to an acceptable method of contraception throughout the study
Exclusion
- Currently receiving medication for the treatment of tardive dyskinesia
- Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias
- Have a serious untreated or undertreated psychiatric illness
- Have recent history or presence of violent behavior
- Have unstable or serious medical illness
- Have evidence of hepatic impairment
- Have evidence of renal impairment
- Have known allergy to any component of SD-809 or tetrabenazine
- Has participated in an investigational drug or device trial and received study drug or device within 30 days
- Have acknowledged use of illicit drugs
- Have a history of alcohol or substance abuse in the previous 12 months
Key Trial Info
Start Date :
October 31 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2016
Estimated Enrollment :
298 Patients enrolled
Trial Details
Trial ID
NCT02291861
Start Date
October 31 2014
End Date
August 19 2016
Last Update
November 9 2021
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Teva Investigational Site 145
Tuscaloosa, Alabama, United States, 35404
2
Teva Investigational Site 107
Anaheim, California, United States, 92804
3
Teva Investigational Site 108
Anaheim, California, United States, 92805
4
Teva Investigational Site 123
Glendale, California, United States, 91206